Surgical Technology and Clinical Trials
Mike Chen, M.D., Ph.D.
Dr. Chen, Associate Professor at the Division of Neurosurgery, received his M.D. from Thomas Jefferson University and a M.S. in Biomedical Engineering. He specializes in complex operations for the removal of brain and spine tumors. His laboratory investigates epigenetic pathways of metastasis and the development of novel medical devices.
Dr. Chen, Associate Professor at the Division of Neurosurgery, received his M.D. from Thomas Jefferson University and a M.S. in Biomedical Engineering. He specializes in complex operations for the removal of brain and spine tumors. His laboratory investigates epigenetic pathways of metastasis and the development of novel medical devices.
Thanh Dellinger, M.D.
Dr. Dellinger, Assistant Professor at the Department of Surgery, received her M.D. from University of California Irvine School of Medicine. Dr. Dellinger's research focuses on understanding the molecular pathways leading to ovarian and uterine cancers and the development of therapies to interdict these processes.
Dr. Dellinger, Assistant Professor at the Department of Surgery, received her M.D. from University of California Irvine School of Medicine. Dr. Dellinger's research focuses on understanding the molecular pathways leading to ovarian and uterine cancers and the development of therapies to interdict these processes.
Rahul Jandial, M.D., Ph.D.
Dr. Jandial, Associate Professor at the Department of Surgery, received his M.D. and Ph.D. from USC and UC San Diego, respectively. He is interested in understanding the interplay between the brain microenvironment and metastatic cancer cells. He is also investigating the efficacy of a potential chemotherapeutic agent for treating metastatic brain cancer.
Dr. Jandial, Associate Professor at the Department of Surgery, received his M.D. and Ph.D. from USC and UC San Diego, respectively. He is interested in understanding the interplay between the brain microenvironment and metastatic cancer cells. He is also investigating the efficacy of a potential chemotherapeutic agent for treating metastatic brain cancer.
Keane Lai, M.D.
Dr. Lai, Associate Clinical Professor at the Department of Pathology, received his M.D. from University of Pittsburgh. Dr. Lai is interested in defining the role that the Wnt/β-catenin signaling pathway plays in liver cancer and pancreatic cancer. His laboratory is also working toward identifying novel therapeutic targets in this pathway to combat pancreatic cancer.
Dr. Lai, Associate Clinical Professor at the Department of Pathology, received his M.D. from University of Pittsburgh. Dr. Lai is interested in defining the role that the Wnt/β-catenin signaling pathway plays in liver cancer and pancreatic cancer. His laboratory is also working toward identifying novel therapeutic targets in this pathway to combat pancreatic cancer.
Flavia Pichiorri, Ph.D.
Dr. Pichiorri, Associate Professor at the Center for Multiple Myeloma Research, received her Ph.D. from University of Rome. Her team works closely with the clinical team to investigate the molecular changes associated with the clinical response of multiple myeloma patients in the investigator-initiated phase 1-2 clinical trials.
Dr. Pichiorri, Associate Professor at the Center for Multiple Myeloma Research, received her Ph.D. from University of Rome. Her team works closely with the clinical team to investigate the molecular changes associated with the clinical response of multiple myeloma patients in the investigator-initiated phase 1-2 clinical trials.
Christiane Querfeld, M.D., Ph.D.
Dr. Querfeld, Chief of Division of Dermatology and Associate Professor at the Department of Surgery, received her M.D. and Ph.D. from University of Cologne and University of Heidelberg, respectively. Dr. Querfeld's research focuses on understanding the biology of cutaneous lymphomas and developing therapies for this class of cancer.
Dr. Querfeld, Chief of Division of Dermatology and Associate Professor at the Department of Surgery, received her M.D. and Ph.D. from University of Cologne and University of Heidelberg, respectively. Dr. Querfeld's research focuses on understanding the biology of cutaneous lymphomas and developing therapies for this class of cancer.
Dan J. Raz. M.D., M.A.S.
Dr. Raz, Associate Clinical Professor, at the Department of Surgery, specializes in lung cancer surgery. His team is targeting specific epigenetic marks to overcome therapy resistance in lung cancer. He is active in drug discovery and use of human lung cancer tissue to test new therapeutics including 3D cell culture, tissue slice culture, and patient-derived xenografts.
Dr. Raz, Associate Clinical Professor, at the Department of Surgery, specializes in lung cancer surgery. His team is targeting specific epigenetic marks to overcome therapy resistance in lung cancer. He is active in drug discovery and use of human lung cancer tissue to test new therapeutics including 3D cell culture, tissue slice culture, and patient-derived xenografts.
Russell Rockne, Ph.D.
Dr. Rockne, Assistant Professor at the Department of Computational and Quantitative Medicine, received his Ph.D. from University of Washington. His work is based upon patient-specific mathematical models of cancer growth and response to therapy, with the goal of using mathematical models to quantify and predict disease dynamics and recurrence.
Dr. Rockne, Assistant Professor at the Department of Computational and Quantitative Medicine, received his Ph.D. from University of Washington. His work is based upon patient-specific mathematical models of cancer growth and response to therapy, with the goal of using mathematical models to quantify and predict disease dynamics and recurrence.
Steven Rosen, M.D.
Dr. Rosen, Provost & Professor at the Department of Hematology & Hematopoietic Cell Transplantation, received his M.D. from Northwestern University. His team is developing novel therapies for hematologic malignancy by targeting ATP synthase, dihydroorotate dehydrogenase, histone deacetylase and de-ubiquinase.
Dr. Rosen, Provost & Professor at the Department of Hematology & Hematopoietic Cell Transplantation, received his M.D. from Northwestern University. His team is developing novel therapies for hematologic malignancy by targeting ATP synthase, dihydroorotate dehydrogenase, histone deacetylase and de-ubiquinase.
Edward Wenge Wang, M.D., Ph.D.
Dr. Wang, Assistant Professor and Medical Oncologist at the Department of Medical Oncology and Therapeutics Research, received his MD, PhD from Harbin Medical University. He leads a laboratory at the Biomedical Research Center, focusing on development of new death receptor agonists and rescue of p53 from negative regulators for cancer treatment.
Dr. Wang, Assistant Professor and Medical Oncologist at the Department of Medical Oncology and Therapeutics Research, received his MD, PhD from Harbin Medical University. He leads a laboratory at the Biomedical Research Center, focusing on development of new death receptor agonists and rescue of p53 from negative regulators for cancer treatment.
Leo Wang, M.D., Ph.D.
Dr. Wang, Assistant Professor at the Department of Immuno-Oncology, received his MD and PhD from the University of Chicago. Dr. Wang's lab uses molecular and cellular techniques to identify non-genetic determinants leading to functional differences in blood cells at different stages of development.
Dr. Wang, Assistant Professor at the Department of Immuno-Oncology, received his MD and PhD from the University of Chicago. Dr. Wang's lab uses molecular and cellular techniques to identify non-genetic determinants leading to functional differences in blood cells at different stages of development.
Yuan Yuan, M.D., Ph.D.
Dr. Yuan, Associate Professor at the Department of Medical Oncology and Therapeutics Research, receive her M.D. and Ph.D. from Xuzhou Medical College and UC Riverside, respectively. She is interested in developing novel therapeutics for metastatic triple negative breast cancer. She is currently involved in a number of clinical trials testing these therapies.
Dr. Yuan, Associate Professor at the Department of Medical Oncology and Therapeutics Research, receive her M.D. and Ph.D. from Xuzhou Medical College and UC Riverside, respectively. She is interested in developing novel therapeutics for metastatic triple negative breast cancer. She is currently involved in a number of clinical trials testing these therapies.